Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that it has completed a $25 million Seed Funding to finalize its ongoing IND-enabling activities for its lead program, BTM-3566, and consummate preparations for first in human clinical trials.  The funding was co-led by Bantam's current investors.

Bantam Pharmaceutical is a privately funded biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for difficult-to-treat hematological and solid tumors.  The Company's current clinical development strategy is focused on B-cell hematological malignancies with expansion into additional patient cohorts based on responses in biomarker-selected patient populations.

Bantam Pharmaceutical Completes $25 Million Seed Funding To Finalize Preclinical Development And Prepare For First In Humans Trials

Description

Company Information

Funding Insights

Bantam Pharmaceutical Completes $25 Million Seed Funding To Finalize Preclinical Development And Prepare For First In Humans Trials

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information